Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Laboratorios Hipra S A has 2 pending office actions in Biotechnology & Pharmaceuticals. The record spans 2 distinct examiners and 2 distinct art units, so the matters are distributed across separate examination contexts.
HILL, MYRON G is the busiest examiner, with 1 pending matter. Application-level prosecution planning is appropriate because neither the examiner nor the art unit is shared across the pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558680 | SARS-COV-2 SUBUNIT VACCINE | SALVOZA, M FRANCO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558875 | SARS-COV-2 SUBUNIT VACCINE | HILL, MYRON G | 4d overdue |
| 18558680 | SARS-COV-2 SUBUNIT VACCINE | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558875 | SARS-COV-2 SUBUNIT VACCINE | HILL, MYRON G | 1671 | §103DP | Final Rejection | 4d overdue | Pending | Nov 03, 2023 |
| 18558680 | SARS-COV-2 SUBUNIT VACCINE | SALVOZA, M FRANCO G | 1672 | §103§112Other | Final Rejection | — | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLaboratorios Hipra S A has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Myron G Hill has the most, with 1 of Laboratorios Hipra S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
